Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 964 | 1083 | 964 | 592 | - | - |
Fund Return | -3.55% | 8.32% | -3.55% | -16.05% | - | - |
Place in category | 169 | 165 | 169 | 132 | - | - |
% in Category | 80 | 74 | 80 | 84 | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Global Income Fund C div USD hedged | 16.57B | 0.62 | 2.00 | 4.30 | ||
JPI Global Income Fund C dist USD h | 16.57B | 0.62 | 1.99 | 4.25 | ||
Global Income Fund D div USD hedged | 16.57B | 0.64 | -0.15 | 3.09 | ||
JPI Global Income Fund C mth USD he | 16.57B | 1.00 | 0.88 | 4.14 | ||
JPI Global Income Fund D acc USD he | 16.57B | 0.65 | -0.13 | 3.12 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Biotech Discovery Nacc | 108.27M | 4.88 | -4.60 | 3.64 | ||
Pictet Biotech PUSD | 1.51B | -18.50 | 5.47 | 7.18 | ||
Pictet Biotech R USD | 1.51B | -18.92 | 4.74 | 6.44 | ||
Equities L Biotechnology Class I US | 1.48B | 2.72 | 2.18 | 7.26 | ||
Equities L Biotechnology Class R US | 1.48B | 2.99 | 2.98 | 7.71 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Alnylam | US02043Q1076 | 3.31 | 148.43 | -1.07% | |
Vertex | US92532F1003 | 3.18 | 455.34 | +2.77% | |
Amgen | US0311621009 | 3.12 | 305.85 | +1.61% | |
Novartis | CH0012005267 | 3.08 | 92.77 | -0.43% | |
Biomarin Pharma | US09061G1013 | 3.04 | 75.07 | +0.79% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review